- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07549516
Een studie naar de verdraagbaarheid, veiligheid en effectiviteit van asciminib bij patiënten met Philadelphia-chromosoom-positieve chronische myeloïde leukemie in de chronische fase in Duitsland (ASC2ADHERE)
Een niet-interventionele studie naar de verdraagbaarheid, veiligheid en effectiviteit van Asciminib bij nieuw gediagnosticeerde en voorbehandelde patiënten met Philadelphia-chromosoom-positieve chronische myeloïde leukemie in de chronische fase in Duitsland - de ASC2ADHERE-studie
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Novartis Pharmaceuticals
- Telefoonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Studie Contact Back-up
- Naam: Novartis Pharmaceuticals
Studie Locaties
-
-
-
Amberg, Duitsland, 92224
- Werving
- Novartis Investigative Site
-
Bad Friedrichshall, Duitsland, 74177
- Werving
- Novartis Investigative Site
-
Bad Liebenwerda, Duitsland, 04924
- Werving
- Novartis Investigative Site
-
Bad Saarow, Duitsland, 15526
- Werving
- Novartis Investigative Site
-
Berlin, Duitsland, 10437
- Werving
- Novartis Investigative Site
-
Berlin, Duitsland, 10365
- Werving
- Novartis Investigative Site
-
Berlin, Duitsland, 12552
- Werving
- Novartis Investigative Site
-
Berlin, Duitsland, 10559
- Werving
- Novartis Investigative Site
-
Berlin, Duitsland, 12487
- Werving
- Novartis Investigative Site
-
Bremerhaven, Duitsland, 27568
- Werving
- Novartis Investigative Site
-
Buchholz Nordheide, Duitsland, 21244
- Werving
- Novartis Investigative Site
-
Cottbus, Duitsland, 03046
- Werving
- Novartis Investigative Site
-
Deggendorf, Duitsland, 94469
- Werving
- Novartis Investigative Site
-
Detmold, Duitsland, 32756
- Werving
- Novartis Investigative Site
-
Dorfen, Duitsland, 84405
- Werving
- Novartis Investigative Site
-
Dortmund, Duitsland, 44263
- Werving
- Novartis Investigative Site
-
Dresden, Duitsland, 01307
- Werving
- Novartis Investigative Site
-
Dresden, Duitsland, 01127
- Werving
- Novartis Investigative Site
-
Düren, Duitsland, 52353
- Werving
- Novartis Investigative Site
-
Erfurt, Duitsland, 99085
- Werving
- Novartis Investigative Site
-
Erfurt, Duitsland, 99084
- Werving
- Novartis Investigative Site
-
Eschweiler, Duitsland, 52249
- Werving
- Novartis Investigative Site
-
Göttingen, Duitsland, 37073
- Werving
- Novartis Investigative Site
-
Hanover, Duitsland, 30161
- Werving
- Novartis Investigative Site
-
Hanover, Duitsland, 30625
- Werving
- Novartis Investigative Site
-
Hildesheim, Duitsland, 31135
- Werving
- Novartis Investigative Site
-
Kiel, Duitsland, 24105
- Werving
- Novartis Investigative Site
-
Leipzig, Duitsland, 04103
- Werving
- Novartis Investigative Site
-
Leverkusen, Duitsland, 51375
- Werving
- Novartis Investigative Site
-
Mutlangen, Duitsland, 73557
- Werving
- Novartis Investigative Site
-
Naunhof, Duitsland, 04683
- Werving
- Novartis Investigative Site
-
Neuss, Duitsland, 41462
- Werving
- Novartis Investigative Site
-
Offenburg, Duitsland, 77654
- Werving
- Novartis Investigative Site
-
Oldenburg, Duitsland, 26121
- Werving
- Novartis Investigative Site
-
Parchim, Duitsland, 19370
- Werving
- Novartis Investigative Site
-
Potsdam, Duitsland, 14467
- Werving
- Novartis Investigative Site
-
Potsdam, Duitsland, 14482
- Werving
- Novartis Investigative Site
-
Schorndorf, Duitsland, 73614
- Werving
- Novartis Investigative Site
-
Schwetzingen, Duitsland, 68723
- Werving
- Novartis Investigative Site
-
Soest, Duitsland, 59494
- Werving
- Novartis Investigative Site
-
Stade, Duitsland, 21680
- Werving
- Novartis Investigative Site
-
Torgau, Duitsland, 04860
- Werving
- Novartis Investigative Site
-
Ulm, Duitsland, 89081
- Werving
- Novartis Investigative Site
-
Wetzlar, Duitsland, 35578
- Werving
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden, Baden-Wurttemberg, Duitsland, 76532
- Werving
- Novartis Investigative Site
-
Heidenheim, Baden-Wurttemberg, Duitsland, 89522
- Werving
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, Duitsland, 74523
- Werving
- Novartis Investigative Site
-
Winnenden, Baden-Wurttemberg, Duitsland, 71364
- Werving
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg, Bavaria, Duitsland, 63739
- Werving
- Novartis Investigative Site
-
Augsburg, Bavaria, Duitsland, 86152
- Werving
- Novartis Investigative Site
-
Donauwörth, Bavaria, Duitsland, 86609
- Werving
- Novartis Investigative Site
-
Herrsching am Ammersee, Bavaria, Duitsland, 82211
- Werving
- Novartis Investigative Site
-
Kempten (Allgäu), Bavaria, Duitsland, 87439
- Werving
- Novartis Investigative Site
-
Landsberg am Lech, Bavaria, Duitsland, 86899
- Werving
- Novartis Investigative Site
-
Munich, Bavaria, Duitsland, 81241
- Werving
- Novartis Investigative Site
-
Munich, Bavaria, Duitsland, 81377
- Werving
- Novartis Investigative Site
-
Regensburg, Bavaria, Duitsland, 93053
- Werving
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven, Free Hanseatic City of Bremen, Duitsland, 27576
- Werving
- Novartis Investigative Site
-
-
Hesse
-
Kassel, Hesse, Duitsland, 34125
- Werving
- Novartis Investigative Site
-
Offenbach, Hesse, Duitsland, 63065
- Werving
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar, Lower Saxony, Duitsland, 38642
- Werving
- Novartis Investigative Site
-
Rotenburg (Wümme), Lower Saxony, Duitsland, 27356
- Werving
- Novartis Investigative Site
-
Twistringen, Lower Saxony, Duitsland, 27239
- Werving
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Duitsland, 50674
- Werving
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Duitsland, 50677
- Werving
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Duitsland, 51103
- Werving
- Novartis Investigative Site
-
Solingen, North Rhine-Westphalia, Duitsland, 42653
- Werving
- Novartis Investigative Site
-
Wesel, North Rhine-Westphalia, Duitsland, 46483
- Werving
- Novartis Investigative Site
-
-
Saxony
-
Zittau, Saxony, Duitsland, 02763
- Werving
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Duitsland, 06110
- Werving
- Novartis Investigative Site
-
Merseburg, Saxony-Anhalt, Duitsland, 06217
- Werving
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Duitsland, 23758
- Werving
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, Duitsland, 04600
- Werving
- Novartis Investigative Site
-
Saalfeld, Thuringia, Duitsland, 07318
- Werving
- Novartis Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
Beschrijving
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Tijdsspanne: Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage van patiënten naar reden voor TKI-behandelbesluit gedocumenteerd door de behandelend arts
Tijdsspanne: Uitgangswaarde
|
Uitgangswaarde
|
|
|
Percentage van patiënten met dosisverlaging naar reden voor dosisverlaging
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Percentage van patiënten met onderbreking van de behandeling per reden van onderbreking
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Percentage van Patiënten die de Behandeling Hebden Gestopt, naar Reden voor Stoppen
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Tijd tot Stopzetting van de Behandeling
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Tijd tot onderbreking van de behandeling
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Tijd tot Dosisverlaging
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Tijd tot Staken van de Behandeling vanwege Bijwerkingen (TSBB)
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
3, 6, 9, 12, 15, 18, 21 en 24 maanden
|
|
|
Percentage of Patients by Clinical Characteristic
Tijdsspanne: Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Tijdsspanne: Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
Tijdsspanne: 3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Tijdsspanne: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Neoplasmata per histologisch type
- Hematologische ziekten
- Leukemie, myeloïde
- Beenmergziekten
- Leukemie
- Myeloproliferatieve aandoeningen
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Leukemie, Myelogeen, Chronisch, BCR-ABL Positief
Andere studie-ID-nummers
- CABL001J1DE02
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .